ROCHESTER, N.Y., Oct. 12, 2007 (PRIME NEWSWIRE) -- VirtualScopics, Inc. (Nasdaq:VSCP), a leading developer of image-based biomarker solutions, announced today that Dr. Edward Ashton, chief scientific officer of VirtualScopics, has been invited to co-chair key discussions at the upcoming Drug Information Association (DIA) medical imaging workshop, to be held October 16-17, 2007, at the Marriott Conference Center in Adelphi, Maryland. The workshop is entitled "Medical Imaging Stakeholders Call for Action: Harmonization of Imaging Review Charters and Integration of Imaging in Therapeutic Development." Dr. Ashton's session will focus on key points to consider when managing imaging site interfaces in clinical trials.
In addition, VirtualScopics' Chief Medical Officer, Dr. Saara Totterman; Chief Technical Officer, Dr. Jose Tamez-Pena and Director of Quality and Regulatory, Toni Handzel have been chosen to participate in working group sessions related to medical imaging good review practices, statistical analysis plans and imaging review charters for image data in clinical trials.
The conference unites the Federal Drug Administration (FDA), pharmaceutical industry and clinical research organizations in order to collaborate for regulatory guidance by standardizing and harmonizing best practices in the use of medical imaging in clinical trials and drug development.
"This meeting presents a unique opportunity to address pivotal issues among pharmaceutical companies, regulatory agencies and imaging core labs. We anticipate that standardizing medical image data analysis will allow for better decision making enabling new drugs to get to market faster," said Dr. Edward Ashton.
"Harmonization and best practice efforts led by the FDA and the pharmaceutical industry clearly demonstrate medical imaging's importance within clinical trials. VirtualScopics is proud to be a key player in this area," said Jeff Markin, chief executive officer of VirtualScopics.
About VirtualScopics, Inc.
VirtualScopics, Inc. is a leading provider of imaging solutions to accelerate drug and medical device development. VirtualScopics has developed a robust software platform for analysis and modeling of both structural and functional medical images. In combination with VirtualScopics' industry-leading experience and expertise in advanced imaging biomarker measurement, this platform provides a uniquely clear window into the biological activity of drugs and devices in clinical trial patients, allowing sponsors to make better decisions faster. For more information about VirtualScopics, visit www.virtualscopics.com.
Forward-Looking Statements
The statements contained in this press release that are not purely historical are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended, and are intended to be covered by the safe harbors created thereby. Forward-looking statements deal with the Company's current plans, intentions, beliefs and expectations. Investors are cautioned that all forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from those in the forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited to, those discussed from time to time in reports filed by the Company with the Securities and Exchange Commission.